Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.45 +0.52 (+1.13%)
Streaming Delayed Price Updated: 11:14 AM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
2 Top Biotech Stocks to Buy in April
Right now you can pick up these stocks on the dip. 
Via The Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
An RSV vaccine could be a driver of blockbuster revenue. 
Via The Motley Fool
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
 
Via Benzinga
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions 
Via Spotlight Growth
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
 
Via Benzinga
GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms
A trial this summer will examine one Zantac user's cancer. 
Via Investor's Business Daily
Why Is Scynexis (SCYX) Stock Up 69% Today?
Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. 
Via InvestorPlace
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
 
Via Benzinga
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
 
Via Benzinga
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
The company says it's refocusing its portfolio to focus on transformational medicines. 
Via Investor's Business Daily
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
 
Via Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
This Is What Whales Are Betting On GSK
 
Via Benzinga
Daily Stock Analysis: GSK
By my dogcatcher ideal, this is a proper time to buy GSK shares, based on their dividends for 2023. 
Via Talk Markets
How Is The Market Feeling About GSK?
 
Via Benzinga
Recent Stock Purchases For March 2023
As readers may know by now, I make stock purchases every single month, no matter what is going on in the world. This month, I went heavier than I normally do, deploying over $3,000. Let's take a look. 
Via Talk Markets
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
 
Via Benzinga
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
The best pharma stocks to buy are those that are poised to be greatly boosted by drugs that are well-positioned to become blockbusters. 
Via InvestorPlace
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
An approved RSV vaccine could be the next big thing for these companies. 
Via The Motley Fool
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D... 
Via Benzinga
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
From GSK plc
Via Business Wire
3 High Dividend Stocks With Attractive Total Return Potential
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns. 
Via InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
This vaccine candidate could help tackle the respiratory syncytial virus. 
Via The Motley Fool
March 2023 Stock Considerations
The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock... 
Via Talk Markets
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.